26 Feb 2008 - MorphoSys AG announced that Astellas Pharma Inc. has decided to extend the current collaboration between the two companies. The collaboration, originally signed in March 2007, will now run its full term. Under the agreement, which is now extended for four more years until March 2012, Astellas will continue to have access to MorphoSys's proprietary antibody library HuCAL GOLD at its research site in Tsukuba, Japan. Furthermore, the extension includes an option for Astellas to develop and commercialize HuCAL-derived therapeutic antibodies, in which case MorphoSys would receive exclusive license fees, milestone payments, as well as royalties. Under the extended agreement MorphoSys continues to receive annual user fees for access to its HuCAL platform. Further financial details were not disclosed.
 |
www.bionity.com/news/e/78613 |
|
 |
|
|
© Chemie.DE Information Service GmbH http://www.bionity.com/news/e/78613 |
Seydelstr. 28 · 10117 Berlin info@chemie.de · Tel: +49 (0)30 20 45 68 - 0 |